Operational Excellence (OPEX) Insight – Thursday - July 23, 2026: A 100% Pharma Tariff Lands July 31: Reprice, Reshore, or Absorb.
Góc Nhìn Vận Hành Xuất Sắc – Thứ Năm, Ngày 23/07/2026: Thuế Dược 100% Ập Đến Ngày 31/7: Tăng Giá, Dời Nhà Máy, Hay Tự Gánh.
Welcome To Operational Excellence (OPEX) Insight Article For The Paid Subscriber-Only Edition.
This is the bilingual post in English and Vietnamese. Vietnamese is below.
Đây là bài viết song ngữ Anh-Việt. Tiếng Việt ở bên dưới.
English
PART 1 – OFFICIAL INFORMATION
In just over a week, the pharmaceutical industry will face one of the largest cost shocks in years. According to the information released, a 100% tariff will begin to take effect on July 31 for several major pharmaceutical companies, and full-scale implementation is expected to begin in September. A tariff equal to 100% means the import cost of the affected goods can double almost overnight, and for an industry whose supply chain spans the globe, this is not a minor adjustment but a make-or-break test of operational capability.
The first thing worth noting is the magnitude of the number. Most import tariffs businesses are used to dealing with range from a few percent to a few dozen percent, enough to erode margins but rarely enough to overturn an entire business model. A 100% rate is fundamentally different. It is no longer a matter of thinner profit, but of a product potentially losing money the moment it clears customs if there is no response. For thin-margin items, this tariff can wipe out all profit and push the product below breakeven.
The second thing worth noting is how time is compressed. The tariff taking effect on July 31 but reaching full-scale implementation in September creates two very close milestones, and both leave very little room to maneuver. Building a new factory, shifting supply to another location, or renegotiating every contract are all things measured in months and years, not weeks. The gap between learning the news and the tariff landing is too narrow to do any of that, so the short-term response is forced onto operational levers that can be activated quickly.
The third thing worth noting is the nature of the industry being targeted. Pharmaceuticals are not an ordinary commodity. They are tied to human health, subject to strict regulation of quality and origin, and have long, complex supply chains where the active ingredient is made in one place, formulated in another, then packaged and distributed in a third. Moving one link of that chain to another country is not as simple as relocating an assembly line, because every drug-manufacturing site must pass regulatory assessment and approval, a process that is inherently long. This significantly narrows the quick escapes that other industries might use.
Faced with such a shock, a business essentially has only three groups of responses, and none is comfortable. The first is to absorb the cost, that is, accept thinner margins or losses to hold prices and hold market share, an option sustainable only for a short time. The second is to pass the cost into the selling price, that is, raise drug prices, something highly sensitive socially and liable to provoke reaction from buyers and regulators alike. The third is to change the supply chain, moving production home or to a place not subject to the tariff, a direction correct in the long run but nearly impossible in a few weeks.
Precisely because all three paths carry their own cost, the real question is not choosing a single path, but coordinating all three intelligently over time: where to absorb, how much to raise prices, and how to begin shifting the supply chain in time. This is not a decision for procurement, sales, or finance alone, but a problem that requires all three at the same table. And to solve it with discipline rather than panic, you need an operational tool born precisely to balance supply, demand, and finance within one plan.
